In fact, evidence has established that lapatinib, a dual inhibitor of EGFR and erb-b2 receptor tyrosine kinase 2, has a synergistic effect in NPC cells with an eEF-2 inhibitor by downregulating the SRC signaling pathway (47). Here, ERBB2 is linked to nasopharyngeal carcinoma.